<DOC>
	<DOCNO>NCT00848640</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Sorafenib first line treatment patient - unsuitable another approve first line therapy - advanced RCC Middle East Region .</brief_summary>
	<brief_title>Study Sorafenib Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . The patient must provide write informed consent prior receive Sorafenib . 2 . The male female patient must least 18 year age . 3 . The patient must pathologically prove advanced Renal Cell Carcinoma . 4 . Only patient measurable disease ( According RECIST ) baseline include protocol Disease Control Rate ( DCR ) primary endpoint . 5 . The patient require Sorafenib First line therapy patient unsuitable another approve first line therapy advance RCC . 6 . The patient must , Investigator 's opinion , reasonably likely benefit treatment Sorafenib single agent . 7 . The patient must Eastern Cooperative Oncology Group performance status 0 2 . 8 . The patient require systemic anticancer chemotherapy , immunotherapy hormonal therapy , except bisphosphonates take Sorafenib . 9 . Both male female patient must use adequate barrier birth control method participation protocol . The birth control method must use 4 week female patient 3 month male patient discontinuation treatment Sorafenib . 10 . For patient , major surgery , wound must completely heal prior receive Sorafenib treatment ( 4 week ) . 11 . The patient must within normal Renal &amp; Hepatic function . 12 . The patient must within normal CBC . 1 . Patients currently enrol previously participate Sorafenib trial . 2 . Suitable received systemic therapy treatment RCC ( IL2 , INF ) 3 . Patients life expectancy le 2 month . 4 . Patients metastatic brain meningeal tumour . 5 . Patients exclude require following : Investigational drug therapy treatment Sorafenib within 30 day prior first dose Sorafenib . Concomitant Rifampicin . 6 . Nonmeasurable disease accord RECIST . 7 . Concomitant St. John 's Wort ( Hypericum perforatum ) . 8 . Warfarin ( similar medication ) allow . 9 . Women pregnant breastfeeding . Women childbearing potential must negative pregnancy test perform within seven day start study drug ( please note laboratory data collect study ) . 10 . Patients congestive heart failure great NYHA functional class II ( symptomatic ordinary activity ) 11 . Patients cardiac arrhythmias great Grade 1 NCI CTCAE , Version 3.0 ( conduction abnormality supraventricular arrhythmia present patient asymptomatic ; intervention indicate , palpitation present QTc &gt; 0.45 0.47 second ) . 12 . Patients active coronary artery disease ischemia . 13 . Patients ChildPugh class C hepatic impairment . 14 . Patients severe renal impairment ( calculated creatinine clearance &lt; 30 ml/min ) require dialysis . 15 . Patients active uncontrolled hypertension . 16 . Patients recent active bleeding diathesis . 17 . Patients medical condition could jeopardize safety take investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>